HCM
MRNA icon

Hollencrest Capital Management’s Moderna MRNA Stock Holding History

Hollencrest Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$42 – 1196
2024
Q4 		$42 Hold
1
– – ﹤0.01% 1148
2024
Q3 		$67 Buy
+1
New +$92 ﹤0.01% 1085
2024
Q2 		– Sell
-55
Closed -$5.86K – 1137
2024
Q1 		$5.86K Hold
55
– – ﹤0.01% 787
2023
Q4 		$5.47K Sell
55
-40
-42% -$3.36K ﹤0.01% 796
2023
Q3 		$9.81K Hold
95
– – ﹤0.01% 729
2023
Q2 		$11.5K Buy
95
+35
+58% +$4.67K ﹤0.01% 736
2023
Q1 		$9.21K Sell
60
-9
-13% -$1.49K ﹤0.01% 754
2022
Q4 		$12.4K Buy
+69
New +$11.3K ﹤0.01% 694
2021
Q4 		– Sell
-1,795
Closed -$690K – 402
2021
Q3 		$690K Buy
1,795
+502
+39% +$185K 0.06% 157
2021
Q2 		$304K Buy
+1,293
New +$231K 0.03% 269

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hollencrest Capital Management's MRNA Position: Q1 2025 in Review

Hollencrest Capital Management sold out of Moderna (MRNA) in Q1 2025, closing a stake of 1 share — an estimated $42 sold.

Hollencrest Capital Management first reported a position in MRNA in Q2 2021 and held it in 10 quarters. The position peaked at $690K in Q3 2021. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Hollencrest Capital Management reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Hollencrest Capital Management sold 1 Moderna share in Q1 2025, an estimated $42.
  • Hollencrest Capital Management first reported a position in Moderna in Q2 2021 and held it in 10 quarters.
  • Hollencrest Capital Management's Moderna position peaked at $690K in Q3 2021.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Hollencrest Capital Management's 13F filing for Q1 2025, filed 5 May 2025.